Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics
BridgeBio is snatching a recently-abandoned cancer program off Novartis’ shelves, handing the asset to a spinout company with unusual plans for the drug.
The newly-licensed product — called infigratinib or BGJ398 — was in Phase II trials at Novartis for patients with bile duct cancer with FGFR fusions. Although the drug showed meaningful clinical activity early in the trial, Novartis decided to dump the drug last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.